NCT06610734View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

Adebrelimab

Adebrelimab combined with chemotherapy synchronous LDRT

DRUG

Chemotherapy

Chemotherapy

RADIATION

low dose radiotherapy

low dose radiotherapy

All Listed Sponsors
collaborator

Shanghai Shengdi Pharmaceutical Co., Ltd

INDUSTRY

lead

Sichuan University

OTHER

NCT06610734 - Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC | Biotech Hunter | Biotech Hunter